What's new? Log in Free sign up

DexCom (DXCM)

Company Profile

Company profile

Ticker

DXCM

Exchange

Website

CEO

Mr. Kevin Ronald Sayer

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Becton, Dickinson and • Baxter International • Ares Capital • Stryker • Boston Scientific • Solventum • Teleflex • Hercules Capital • ResMed ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

DEXCOM INTERNATIONAL LIMITED • ROADRUNNER GREEN LIMITED • DEXCOM (MALAYSIA) SDN. BHD. ...

IRS number

330857544

DXCM stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$101.33

Low target

$100.00

High target

$102.00

Truist Securities

Latest filings (excl ownership)

View all

Conflict minerals disclosure

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

Departure of Directors or Certain Officers

Registration of securities for employees

Departure of Directors or Certain Officers

Additional proxy soliciting materials

Departure of Directors or Certain Officers

Quarterly report

1 May 25

Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

Annual report to shareholders

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Michael Jon Brown

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Michael Jon Brown

NICHOLAS AUGUSTINOS

Financial summary

Financial statements Chart DXCM financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from DexCom earnings reports.

Institutional ownership, Q4 2024

DXCM institutional ownership history Ownership history

90.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	931	883	+5.4%
Opened positions	186	103	+80.6%
Closed positions	138	207	-33.3%
Increased positions	324	325	-0.3%
Reduced positions	327	347	-5.8%

13F shares	Current	Prev Q	Change
Total value	26.84 tn	22.82 tn	+17.6%
Total shares	356.01 mm	352.12 mm	+1.1%
Total puts	5.73 mm	5.59 mm	+2.4%
Total calls	8.37 mm	5.51 mm	+52.0%
Total put/call ratio	0.7	1.0	-32.6%

Largest owners	Shares	Value	Change
Vanguard	46.53 mm	$3.62 tn	-1.9%
BlackRock	39.60 mm	$3.08 tn	+13.1%
STT State Street	16.69 mm	$1.30 tn	+0.1%
Baillie Gifford & Co	14.61 mm	$1.14 tn	-2.7%
Capital Research Global Investors	14.37 mm	$1.12 tn	-19.9%
Sands Capital Management	11.11 mm	$863.99 bn	+7.7%
Geode Capital Management	9.99 mm	$775.26 bn	+0.6%
Nuveen Asset Management	8.14 mm	$632.93 bn	+0.6%
Jennison Associates	7.64 mm	$594.45 bn	+10.3%
Ubs Global Asset Management Americas	7.20 mm	$559.81 bn	+13.4%

Largest transactions	Shares	Bought/sold	Change
Wellington Management	25.84 k	-5.67 mm	-99.5%
Norges Bank	4.96 mm	+4.96 mm	NEW
BlackRock	39.60 mm	+4.57 mm	+13.1%
Capital World Investors	3.84 mm	-3.79 mm	-49.6%
Capital Research Global Investors	14.37 mm	-3.58 mm	-19.9%
Citadel Advisors	4.26 mm	+3.03 mm	+245.4%
Millennium Management	3.08 mm	+2.73 mm	+800.3%
RJF Raymond James Financial	2.72 mm	+2.72 mm	NEW
MS Morgan Stanley	6.91 mm	+1.65 mm	+31.4%
Point72 Asset Management	1.60 mm	+1.60 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DXCM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jul 25	Micheal Jon Brown	Common Stock	Sell	Dispose S	No	Yes	86.03	500	43.02 k	94,602
15 Jul 25	Mark G Foletta	Common Stock	Sell	Dispose S	Yes	No	86.03	8	688.24	53,871
15 Jul 25	Mark G Foletta	Common Stock	Sell	Dispose S	Yes	Yes	85.1672	2,742	233.53 k	53,879
26 Jun 25	Sadie Stern	Common Stock	Sell	Dispose S	No	Yes	85.06	1,466	124.70 k	108,155
16 Jun 25	Micheal Jon Brown	Common Stock	Sell	Dispose S	No	Yes	82.8	500	41.40 k	95,102
16 Jun 25	Mark G Foletta	Common Stock	Sell	Dispose S	Yes	Yes	83.129	2,750	228.60 k	56,621

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Mizuho Maintains Outperform on DexCom, Raises Price Target to $100

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $95 to $100.

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes

An update on Sana Biotechnology.

What Does the Market Think About DexCom?

Price Over Earnings Overview: DexCom

Watching Stocks Involved In Wearable Health Devices; Traders Circulate X Post Saying "RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). his vision is every American wearing "wearable" in 4 years... HUGE COIs here with some of his top advisors & their businesses."

Press releases

From Benzinga Pro

Ainnova Tech Reaches Major FDA Milestone in AI-Powered Diabetic Retinopathy Detection

Revolutionary Vision AI platform moves closer to US market approval following successful FDA pre-submission meetingThe healthcare technology landscape took a significant step forward this week as Ainnova Tech, Inc., in

Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related

Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ:DXCM) for

Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders

Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.